# EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

> **NCT00448305** · PHASE2 · COMPLETED · sponsor: **MediGene** · enrollment: 143 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** EndoTAG-1 + paclitaxel
- **DRUG:** EndoTAG-1
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00448305
- **Lead sponsor:** MediGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-02
- **Final completion:** 2011-03
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2012-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448305, "EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00448305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*